Shareholders of German family-owned pharma major Boehringer Ingelheim have decided to appoint Simone Menne to the firm’s board of managing directors with effect from September 1, 2016.
On this date she will assume responsibility for the corporate board division finance. She succeeds Hubertus von Baumbach who, as previously announced, will become chairman of the board of managing directors on July 1, 2016. He will also continue to be responsible for the corporate board division finance until August 31, 2016.
Christian Boehringer, chairman of the Shareholders' Committee, states: “Ms Simone Menne is a distinguished figure in the field of finance with many years of successful experience in Germany and abroad. Previously, she held strategic and operational responsibility in various roles. She is therefore thoroughly familiar with the key tasks and challenges faced by a multinational corporation based in Germany.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze